Ammon Roberts, DO
Family Medicine · Boise, IDNPI 1225693666
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.4% of the total across 298 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 38 manufacturers, the largest accounting for just 21.4% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $2,181, more than ten times the $13 reported in 2019. Among family medicine clinicians in ID with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 298 payments — averaging $23.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$2K
- Pfizer$844
- AstraZeneca$817
- AbbVie$594
- Lilly USA, LLC$385
- GSK$312
- plus $3K from 32 others
What the payments were for
- Food & beverage$6,98099%
- Education$451%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 30 | $1,504 |
| Pfizer | 46 | $844 |
| AstraZeneca | 26 | $817 |
| AbbVie | 34 | $594 |
| Lilly USA, LLC | 24 | $385 |
| GSK | 21 | $312 |
| Novo Nordisk | 17 | $291 |
| Axsome Therapeutics, Inc. | 6 | $244 |
| Bayer | 8 | $237 |
| Otsuka America Pharmaceutical, Inc. | 11 | $218 |
| Exact Sciences | 11 | $198 |
| Novartis | 8 | $168 |
| Boehringer Ingelheim | 6 | $132 |
| Antares Pharma, Inc. | 6 | $120 |
| Johnson & Johnson | 6 | $109 |
| Gilead | 1 | $104 |
| Dexcom, Inc. | 2 | $83 |
| Astellas Pharma US Inc | 3 | $68 |
| Halozyme Inc | 3 | $65 |
| Xeris Pharmaceuticals, Inc. | 3 | $61 |
| Insulet Corporation | 2 | $49 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $47 |
| Mayne Pharma Commercial LLC | 2 | $44 |
| Phathom Pharmaceuticals, Inc. | 3 | $42 |
| Kerecis Limited | 1 | $35 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $35 |
| Merck | 2 | $32 |
| Abbott | 1 | $21 |
| Acadia Pharmaceuticals Inc | 1 | $21 |
| Boston Scientific | 1 | $19 |
| Organon | 1 | $18 |
| Sanofi-aventis U.S. LLC | 1 | $17 |
| Teva Pharmaceuticals USA, Inc. | 1 | $16 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $16 |
| Hologic Sales And Service, LLC | 1 | $16 |
| Idorsia Pharmaceuticals US Inc | 1 | $14 |
| Medtronic | 1 | $14 |
| E.r. Squibb & Sons, L.L.C. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,025 in reported general payments places this provider in the 95th percentile of 803 family medicine providers in Idaho.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 41 | $49,977 |
| EliquisApixaban | 32 | $34,277 |
| JardianceEmpagliflozin | 20 | $28,025 |
| TrulicityDulaglutide | 13 | $17,257 |
| FarxigaDapagliflozin Propanediol | 20 | $17,143 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 14 | $10,586 |
| Repatha SyringeEvolocumab | 14 | $8,065 |
| SymbicortBudesonide/Formoterol Fumarate | 12 | $2,892 |
| Duloxetine Hcl | 45 | $2,427 |
| Gabapentin | 71 | $1,857 |
| Ezetimibe | 29 | $1,631 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 17 | $1,353 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 68 | $1,303 |
| Clorazepate Dipotassium | 12 | $1,282 |
| Metoprolol Succinate | 70 | $1,180 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $385 | $67,23454 claims |
| PfizerEliquis | $844 | $34,27732 claims |
| Boehringer IngelheimJardiance | $132 | $28,02520 claims |
| AstraZenecaFarxiga, Symbicort | $817 | $20,03432 claims |
| GSKTrelegy Ellipta | $312 | $10,58614 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 803 family medicine providers in Idaho.
Other family medicine in Boise
- Phyllis YouBoise$88K
- Kara CadwalladerBoise$24K
- Cyrus VaniaBoise$9K
- Joshua AdamsBoise$8K
- Nicole StiversBoise$7K
- Ryan MooreBoise$5K
- Mary NagleBoise$4K
- Kenneth CongerSandpoint$266K
- David ButukMeridian$206K
- Anne BroadwayIdaho Falls$184K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.